Does risperidone improve verbal working memory in treatment-resistant schizophrenia?

American Journal of Psychiatry

Volumn 154, Issue 6, 1997, Pages 799-804

  Green, Michael Foster ^a,b   Marshall Jr , B D ^a   Wirshing, William C ^a   Ames, Donna ^a   Marder, Stephen R ^a   McGurk, Susan ^a   Kern, Robert S ^a   Mintz, Jim ^a  

^a UCLA Dept Psychiat B   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZATROPINE MESILATE; HALOPERIDOL; RISPERIDONE; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR;

ADULT; ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; VERBAL MEMORY;

EID: 0030967398     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/ajp.154.6.799     Document Type: Article

References (33)

1. Green MF: What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 1996; 153:321-330
2. Cassens G, Inglis AK, Appelbaum PS, Gutheil TG: Neuroleptics: effects on neuropsychological function in chronic schizophrenic patients. Schizophr Bull 1990; 16:477-499
3. Spohn HE, Strauss ME: Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia. J Abnorm Psychol 1989; 98:367-380
4. Hagger C, Buckley P, Kenny JT, Friedman L, Ubogy D, Meltzer HY: Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol Psychiatry 1993; 34:702-712
5. Buchanan RW, Holstein C, Breier A: The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance. Biol Psychiatry 1994; 36:717-725
6. Goldberg TE, Greenberg RD, Griffin SJ, Gold JM, Kleinman JE, Pickar D, Schulz SC, Weinberger DR: The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. Br J Psychiatry 1993; 162:43-48
7. Hoff AL, Faustman WO, Wieneke M, Espinoza S, Costa M, Wolkowitz O, Csernansky JG: The effects of clozapine on symptom reduction, neurocognitive function, and clinical management in treatment-refractory state hospital schizophrenic inpatients. Neuropsychopharmacology 1996; 15:361-369
8. Marder SR, Meibach RC: Risperidone in the treatment of schizophrenia. Am J Psychiatry 1494; 151:825-835
9. Richelson E: Preclinical pharmacology of neuroleptics: focus on new generation compounds. J Clin Psychiatry 1996; 57(suppl 11):4-11
10. Baddeley AD: Working memory. Science 1992; 255:556-559
11. Shimamura AP: Memory and frontal lobe function, in The Cognitive Neurosciences. Edited by Gazzaniga MS. Cambridge, Mass, MIT Press, 1995, pp 803-815
12. Petrides M, Alivisatos B, Meyer E, Evans AC: Functional activation of the human frontal cortex during the performance of verbal working memory tasks. Proc Natl Acad Sci USA 1993; 90: 878-882
13. Cohen JD, Forman SD, Braver TS, Casey BJ, Servan-Schreiber D, Noll DC: Activation of the prefrontal cortex in a nonspatial working memory task with functional MRI. Human Brain Mapping 1994; 1:293-304
14. Altman HJ, Normile HJ: What is the nature of the role of the serotonergic nervous system in learning and memory: prospects for development of an effective treatment strategy for senile dementia. Neurobiol Aging 1988; 9:627-638
15. Gelenberg AJ, Van Putten T, Lavori PW, Wojcik JD, Falk WE, Marder S, Galvin-Nadeau M, Spring B, Mohs RC, Brotman AW: Anticholinergic effects on memory: benztropine versus amantadine. J Clin Psychopharmacol 1989; 9:180-185
16. Perlick D, Stastny P, Katz I, Mayer M, Mattis S: Memory deficits and anticholinergic levels in chronic schizophrenia. Am J Psychiatry 1986; 143:230-232
17. Sweeney JA, Keilp JG, Haas GL, Hill J, Weiden PJ: Relationships between medication treatments and neuropsychological test performance in schizophrenia. Psychiatry Res 1991; 37:297-308
18. Tune LE, Strauss ME, Lew MF, Breitlinger E, Coyle JT: Serum levels of anticholinergic drugs and impaired recent memory in chronic schizophrenic patients. Am J Psychiatry 1982; 139: 1460-1462
19. Green M, Walker E: Attentional performance in positive- and negative-symptom schizophrenia. J Nerv Ment Dis 1986; 174: 208-213
20. Green MF, Nuechterlein KH, Gaier DJ: Sustained and selective attention in schizophrenia, in Progress in Experimental Personality and Psychopathology Research, vol 15. Edited by Walker EF, Dworkin RH, Cornblatt BA. New York, Springer, 1992, pp 290-313
21. Walker E, Harvey P: Positive and negative symptoms in schizophrenia: attentional performance correlates. Psychopathology 1986; 19:294-302
22. Spitzer RL, Williams JBW, Gibbon M, First MB: Structured Clinical Interview for DSM-III-R - Patient Version 1.0 (SCID-P). Washington, DC, American Psychiatric Press, 1990
23. Kane J, Honigfeld G, Singer J, Meltzer H: Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45:789-796
24. Overall JE, Gorham DR: The Brief Psychiatric Rating Scale. Psychol Rep 1962; 10:799-812
25. Guy W (ed): ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. Rockville, Md, US Department of Health, Education, and Welfare, 1976, pp 217-222
26. Oltmanns TF, Neale JM: Schizophrenic performance when distractors are present: attentional deficit or differential task difficulty? J Abnorm Psychol 1975; 84:205-209
27. Overall JE, Hollister LE, Pichot P: Major psychiatric disorders: a four-dimensional model. Arch Gen Psychiatry 1967; 16:146-161
28. Ventura J, Green MF, Shaner A, Liberman RP: Training and quality assurance with the Brief Psychiatric Rating Scale: "The Drift Busters." Int J Methods in Psychiatr Res 1993; 3:221-224
29. Cochran W: Analysis of covariance: its nature and uses. Biometrics 1957; 13:261-281
30. Littell R, Milliken G, Stroup W, Wolfinger R: SAS Systems for Mixed Models. Cary, NC, SAS Institute, 1996
31. Jennrich R, Schluchter M: Unbalanced repeated-measures models with structured covariance matrices. Biometrics 1986; 42: 805-820
32. Greenblatt DJ, Scavone JM, Harmatz JS, Engelhardt N, Shader RI: Cognitive effects of β-adrenergic antagonists after single doses: pharmacokinetics and pharmacodynamics of propranolol, atenolol, lorazepam, and placebo. Clin Pharmacol Ther 1993; 53:577-584
33. Drachman DA, Leavitt J: Human memory and the cholinergic system. Arch Neurol 1974; 30:113-121